John D Quisel Insider Trading $XLRN ACCELERON PHARMA INC
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for John D Quisel.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of John D Quisel. John D Quisel is EVP, CBO and Secretary in ACCELERON PHARMA INC ($XLRN) and EVP, Chief Business Officer in ACCELERON PHARMA INC ($XLRN) and SVP Gen. Counsel & Secretary in ACCELERON PHARMA INC ($XLRN) and SVP, Bus. Dev., GC & Secretary in ACCELERON PHARMA INC ($XLRN) and SVP, Corp. Dev., GC & Sec. in ACCELERON PHARMA INC ($XLRN) and VP General Counsel & Secretary in ACCELERON PHARMA INC ($XLRN).
John D Quisel in ACCELERON PHARMA INC
Trading Symbol: XLRNIndustry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of John D Quisel: EVP, Chief Business Officer, EVP, CBO and Secretary, SVP, Corp. Dev., GC & Sec., SVP, Bus. Dev., GC & Secretary, SVP Gen. Counsel & Secretary, VP General Counsel & Secretary
Holdings: 57,558 shares
Current Value: $1,366,427
Latest Transaction: Jan 03 2020
$XLRN Market Capitalization: $879.48M
$XLRN Previous Close: $23.74
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of John D Quisel in ACCELERON PHARMA INC
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, Chief Business ... | Sell | S | 52.52 | 4,242 | 222,790 | 53,316 | 57.6 K to 53.3 K (-7.37 %) |
Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, Chief Business ... | Sell | S | 52.51 | 1,600 | 84,016 | 57,558 | 59.2 K to 57.6 K (-2.70 %) |
Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, Chief Business ... | Sell | S | 52.52 | 4,242 | 222,790 | 53,316 | 57.6 K to 53.3 K (-7.37 %) |
Jan 03 2020 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, Chief Business ... | Sell | S | 52.51 | 1,600 | 84,016 | 57,558 | 59.2 K to 57.6 K (-2.70 %) |
Sep 10 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, Chief Business ... | Sell | S | 45.23 | 3,584 | 162,104 | 59,158 | 62.7 K to 59.2 K (-5.71 %) |
Sep 10 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, Chief Business ... | Sell | S | 45.23 | 3,584 | 162,104 | 59,158 | 62.7 K to 59.2 K (-5.71 %) |
Jul 11 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, Chief Business ... | Option Exercise | M | 7.12 | 1,562 | 11,121 | 0 | |
Jul 11 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, Chief Business ... | Option Exercise | M | 5.28 | 2,346 | 12,387 | 0 | |
Jul 11 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, Chief Business ... | Option Exercise | M | 3.88 | 5,000 | 19,400 | 0 | |
Jul 11 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, Chief Business ... | Buy | M | 7.12 | 1,562 | 11,121 | 62,742 | 61.2 K to 62.7 K (+2.55 %) |
Jul 11 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, Chief Business ... | Buy | M | 5.28 | 2,346 | 12,387 | 61,180 | 58.8 K to 61.2 K (+3.99 %) |
Jul 11 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, Chief Business ... | Buy | M | 3.88 | 5,000 | 19,400 | 58,834 | 53.8 K to 58.8 K (+9.29 %) |
Apr 11 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Sell | S | 44.24 | 70 | 3,097 | 53,834 | 53.9 K to 53.8 K (-0.13 %) |
Apr 11 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Sell | S | 45.46 | 100 | 4,546 | 53,904 | 54 K to 53.9 K (-0.19 %) |
Apr 11 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Sell | S | 44.62 | 3,452 | 154,028 | 54,004 | 57.5 K to 54 K (-6.01 %) |
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Option Exercise | A | 41.64 | 28,500 | 1,186,740 | 28,500 | |
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Grant | A | 0.00 | 4,800 | 0 | 57,456 | 52.7 K to 57.5 K (+9.12 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Sell | S | 43.92 | 475 | 20,862 | 52,656 | 53.1 K to 52.7 K (-0.89 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Sell | S | 43.10 | 2,558 | 110,250 | 53,131 | 55.7 K to 53.1 K (-4.59 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Sell | S | 42.31 | 1,300 | 55,003 | 55,689 | 57 K to 55.7 K (-2.28 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Sell | S | 43.26 | 300 | 12,978 | 56,989 | 57.3 K to 57 K (-0.52 %) |
Jan 04 2019 | XLRN | ACCELERON PHARMA I ... | Quisel John D | EVP, CBO and Secret ... | Sell | S | 42.32 | 1,309 | 55,397 | 57,289 | 58.6 K to 57.3 K (-2.23 %) |
Apr 04 2018 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Sell | S | 39.16 | 100 | 3,916 | 56,598 | 56.7 K to 56.6 K (-0.18 %) |
Apr 04 2018 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Sell | S | 38.33 | 1,104 | 42,316 | 56,698 | 57.8 K to 56.7 K (-1.91 %) |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Option Exercise | A | 40.61 | 28,950 | 1,175,660 | 28,950 | |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Grant | A | 0.00 | 4,825 | 0 | 57,802 | 53 K to 57.8 K (+9.11 %) |
Jan 04 2018 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Sell | S | 42.42 | 4,333 | 183,806 | 52,977 | 57.3 K to 53 K (-7.56 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Sell | S | 38.03 | 8 | 304 | 57,310 | 57.3 K to 57.3 K (-0.01 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Sell | S | 39.37 | 600 | 23,622 | 57,318 | 57.9 K to 57.3 K (-1.04 %) |
Sep 14 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Corp. Dev., GC ... | Sell | S | 38.29 | 4,505 | 172,496 | 57,918 | 62.4 K to 57.9 K (-7.22 %) |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Option Exercise | A | 30.17 | 46,300 | 1,396,871 | 46,300 | |
Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Grant | A | 0.00 | 7,900 | 0 | 62,423 | 54.5 K to 62.4 K (+14.49 %) |
Jan 06 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Sell | S | 27.56 | 1,400 | 38,584 | 54,523 | 55.9 K to 54.5 K (-2.50 %) |
Jan 06 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Sell | S | 26.43 | 300 | 7,929 | 55,923 | 56.2 K to 55.9 K (-0.53 %) |
Sep 23 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Option Exercise | M | 3.88 | 11,500 | 44,620 | 5,000 | |
Sep 23 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Option Exercise | M | 24.11 | 13,671 | 329,608 | 15,329 | |
Sep 23 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Option Exercise | M | 7.12 | 781 | 5,561 | 1,562 | |
Sep 23 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Sell | S | 38.05 | 45,952 | 1,748,474 | 56,223 | 102.2 K to 56.2 K (-44.97 %) |
Sep 23 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Buy | M | 3.88 | 11,500 | 44,620 | 102,175 | 90.7 K to 102.2 K (+12.68 %) |
Sep 23 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Buy | M | 24.11 | 13,671 | 329,608 | 90,675 | 77 K to 90.7 K (+17.75 %) |
Sep 23 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Buy | M | 7.12 | 781 | 5,561 | 77,004 | 76.2 K to 77 K (+1.02 %) |
Sep 13 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Option Exercise | M | 7.12 | 4,688 | 33,379 | 2,343 | |
Sep 13 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Option Exercise | M | 5.28 | 6,250 | 33,000 | 0 | |
Sep 13 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Option Exercise | M | 3.88 | 5,500 | 21,340 | 16,500 | |
Sep 13 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Sell | S | 32.14 | 21,438 | 689,017 | 76,223 | 97.7 K to 76.2 K (-21.95 %) |
Sep 13 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Buy | M | 7.12 | 4,688 | 33,379 | 97,661 | 93 K to 97.7 K (+5.04 %) |
Sep 13 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Buy | M | 5.28 | 6,250 | 33,000 | 92,973 | 86.7 K to 93 K (+7.21 %) |
Sep 13 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Buy | M | 3.88 | 5,500 | 21,340 | 86,723 | 81.2 K to 86.7 K (+6.77 %) |
Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | A | 27.97 | 30,800 | 861,476 | 30,800 | |
Mar 07 2016 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Grant | A | 0.00 | 5,100 | 0 | 81,223 | 76.1 K to 81.2 K (+6.70 %) |
Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 3.88 | 5,500 | 21,340 | 22,000 | |
Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 34.17 | 1,400 | 47,838 | 76,123 | 77.5 K to 76.1 K (-1.81 %) |
Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 33.07 | 4,100 | 135,587 | 77,523 | 81.6 K to 77.5 K (-5.02 %) |
Sep 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 3.88 | 5,500 | 21,340 | 81,623 | 76.1 K to 81.6 K (+7.23 %) |
Sep 11 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Grant | A | 0.00 | 40,000 | 0 | 76,123 | 36.1 K to 76.1 K (+110.73 %) |
Aug 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 3.88 | 1,039 | 4,031 | 27,500 | |
Aug 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 4,461 | 26,231 | 0 | |
Aug 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 31.74 | 2,200 | 69,828 | 36,123 | 38.3 K to 36.1 K (-5.74 %) |
Aug 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 30.22 | 3,300 | 99,726 | 38,323 | 41.6 K to 38.3 K (-7.93 %) |
Aug 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 3.88 | 1,039 | 4,031 | 41,623 | 40.6 K to 41.6 K (+2.56 %) |
Aug 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 4,461 | 26,231 | 40,584 | 36.1 K to 40.6 K (+12.35 %) |
Aug 03 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 5,895 | 31,126 | 6,250 | |
Aug 03 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 7,527 | 39,743 | 2,346 | |
Aug 03 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.28 | 5,895 | 31,126 | 36,123 | 30.2 K to 36.1 K (+19.50 %) |
Aug 03 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.28 | 7,527 | 39,743 | 30,228 | 22.7 K to 30.2 K (+33.16 %) |
Jul 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 5,500 | 32,340 | 4,461 | |
Jul 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 30.00 | 5,500 | 165,000 | 22,701 | 28.2 K to 22.7 K (-19.50 %) |
Jul 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 5,500 | 32,340 | 28,201 | 22.7 K to 28.2 K (+24.23 %) |
Jun 18 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 3.88 | 7,701 | 29,880 | 28,539 | |
Jun 18 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 3.88 | 7,701 | 29,880 | 22,701 | 15 K to 22.7 K (+51.34 %) |
Jun 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 5,500 | 32,340 | 9,961 | |
Jun 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 31.13 | 5,500 | 171,215 | 15,000 | 20.5 K to 15 K (-26.83 %) |
Jun 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 5,500 | 32,340 | 20,500 | 15 K to 20.5 K (+36.67 %) |
May 18 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 5,500 | 32,340 | 15,461 | |
May 18 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 31.81 | 3,900 | 124,059 | 15,000 | 18.9 K to 15 K (-20.63 %) |
May 18 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 31.06 | 1,600 | 49,696 | 18,900 | 20.5 K to 18.9 K (-7.80 %) |
May 18 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 5,500 | 32,340 | 20,500 | 15 K to 20.5 K (+36.67 %) |
Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 4,039 | 23,749 | 20,961 | |
Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 1,461 | 8,591 | 0 | |
Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.08 | 4,000 | 20,320 | 0 | |
Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 41.20 | 220 | 9,064 | 15,000 | 15.2 K to 15 K (-1.45 %) |
Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 40.67 | 5,280 | 214,738 | 15,220 | 20.5 K to 15.2 K (-25.76 %) |
Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 4,039 | 23,749 | 20,500 | 16.5 K to 20.5 K (+24.54 %) |
Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 1,461 | 8,591 | 16,461 | 15 K to 16.5 K (+9.74 %) |
Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 42.05 | 800 | 33,640 | 15,000 | 15.8 K to 15 K (-5.06 %) |
Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 41.28 | 3,200 | 132,096 | 15,800 | 19 K to 15.8 K (-16.84 %) |
Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.08 | 4,000 | 20,320 | 19,000 | 15 K to 19 K (+26.67 %) |
Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 5,500 | 32,340 | 1,461 | |
Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.08 | 2,000 | 10,160 | 4,000 | |
Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 1.80 | 2,000 | 3,600 | 0 | |
Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 42.06 | 101 | 4,248 | 15,000 | 15.1 K to 15 K (-0.67 %) |
Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 41.77 | 1,066 | 44,527 | 15,101 | 16.2 K to 15.1 K (-6.59 %) |
Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 40.34 | 4,333 | 174,793 | 16,167 | 20.5 K to 16.2 K (-21.14 %) |
Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 5,500 | 32,340 | 20,500 | 15 K to 20.5 K (+36.67 %) |
Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 42.07 | 1 | 42 | 15,000 | 15 K to 15 K (-0.01 %) |
Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 41.50 | 1,300 | 53,950 | 15,001 | 16.3 K to 15 K (-7.97 %) |
Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 40.65 | 2,699 | 109,714 | 16,301 | 19 K to 16.3 K (-14.21 %) |
Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.08 | 2,000 | 10,160 | 19,000 | 17 K to 19 K (+11.76 %) |
Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 1.80 | 2,000 | 3,600 | 17,000 | 15 K to 17 K (+13.33 %) |
Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 2,438 | 14,335 | 6,961 | |
Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.08 | 1,500 | 7,620 | 6,000 | |
Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 1,562 | 8,247 | 12,145 | |
Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 1.80 | 500 | 900 | 2,000 | |
Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 0.92 | 3,500 | 3,220 | 0 | |
Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 40.12 | 5,500 | 220,660 | 15,000 | 20.5 K to 15 K (-26.83 %) |
Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 2,438 | 14,335 | 20,500 | 18.1 K to 20.5 K (+13.50 %) |
Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.08 | 1,500 | 7,620 | 18,062 | 16.6 K to 18.1 K (+9.06 %) |
Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.28 | 1,562 | 8,247 | 16,562 | 15 K to 16.6 K (+10.41 %) |
Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 40.62 | 500 | 20,310 | 15,000 | 15.5 K to 15 K (-3.23 %) |
Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 39.85 | 3,500 | 139,475 | 15,500 | 19 K to 15.5 K (-18.42 %) |
Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 1.80 | 500 | 900 | 19,000 | 18.5 K to 19 K (+2.70 %) |
Jan 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 0.92 | 3,500 | 3,220 | 18,500 | 15 K to 18.5 K (+23.33 %) |
Jan 09 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | A | 41.20 | 41,000 | 1,689,200 | 41,000 | |
Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 3.88 | 15,000 | 58,200 | 36,240 | |
Dec 19 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 3.88 | 15,000 | 58,200 | 15,000 | 0 to 15 K |
Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 0.92 | 4,000 | 3,680 | 3,500 | |
Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 41.72 | 2,500 | 104,300 | 0 | 2.5 K to 0 (-100.00 %) |
Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 40.72 | 1,500 | 61,080 | 2,500 | 4 K to 2.5 K (-37.50 %) |
Dec 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 0.92 | 4,000 | 3,680 | 4,000 | 0 to 4 K |
Nov 18 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 0.92 | 4,000 | 3,680 | 7,500 | |
Nov 18 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 34.72 | 675 | 23,436 | 0 | 675 to 0 (-100.00 %) |
Nov 18 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 33.24 | 3,325 | 110,523 | 675 | 4 K to 675 (-83.12 %) |
Nov 18 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 0.92 | 4,000 | 3,680 | 4,000 | 0 to 4 K |
Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 7.12 | 1,899 | 13,521 | 7,031 | |
Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 3,101 | 18,234 | 9,399 | |
Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 33.60 | 3,043 | 102,245 | 0 | 3 K to 0 (-100.00 %) |
Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 32.42 | 1,957 | 63,446 | 3,043 | 5 K to 3 K (-39.14 %) |
Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 7.12 | 1,899 | 13,521 | 5,000 | 3.1 K to 5 K (+61.24 %) |
Nov 14 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 3,101 | 18,234 | 3,101 | 0 to 3.1 K |
Oct 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 0.92 | 4,000 | 3,680 | 11,500 | |
Oct 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 29.02 | 4,000 | 116,080 | 0 | 4 K to 0 (-100.00 %) |
Oct 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 0.92 | 4,000 | 3,680 | 4,000 | 0 to 4 K |
Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 7.12 | 3,570 | 25,418 | 8,930 | |
Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 3,430 | 18,110 | 13,707 | |
Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 30.01 | 7,000 | 210,070 | 0 | 7 K to 0 (-100.00 %) |
Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 7.12 | 3,570 | 25,418 | 7,000 | 3.4 K to 7 K (+104.08 %) |
Oct 01 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.28 | 3,430 | 18,110 | 3,430 | 0 to 3.4 K |
Sep 12 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 0.92 | 2,000 | 1,840 | 15,500 | |
Sep 12 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 25.43 | 2,000 | 50,860 | 0 | 2 K to 0 (-100.00 %) |
Sep 12 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 0.92 | 2,000 | 1,840 | 2,000 | 0 to 2 K |
Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 7,863 | 41,517 | 17,137 | |
Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 3,137 | 16,563 | 9,873 | |
Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 0.92 | 2,000 | 1,840 | 17,500 | |
Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 30.02 | 11,000 | 330,220 | 0 | 11 K to 0 (-100.00 %) |
Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.28 | 7,863 | 41,517 | 11,000 | 3.1 K to 11 K (+250.65 %) |
Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.28 | 3,137 | 16,563 | 3,137 | 0 to 3.1 K |
Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 29.79 | 2,000 | 59,580 | 0 | 2 K to 0 (-100.00 %) |
Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 0.92 | 2,000 | 1,840 | 2,000 | 0 to 2 K |
Jul 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 3,000 | 15,840 | 13,010 | |
Jul 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 0.92 | 2,000 | 1,840 | 19,500 |